The Latest Breaking News from William Blair

The U.S. Food and Drug Administration approved on Monday Apellis Pharmaceuticals, Inc.’s (NASDAQ:APLS) Empaveli (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years of age and older, to reduce proteinuria.

Incyte Corporation (NASDAQ:INCY) reported on Tuesday that its second-quarter revenue was $1.22 billion, up 16% year over year. The company beat the consensus of $1.15 billion.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stock is trading higher on Thursday after the company issued an after-hours update on ongoing label expansion efforts for Elevidys, its approved gene therapy for Duchenne muscular dystrophy.

Palantir stock remains in focus as the big data analytics firm teamed up with The Nuclear Company. William Blair recommends caution in buying PLTR shares.

QuantumScape stock soars on successful integration of Cobra separator process into baseline cell production. William Blair recommends selling QS shares before they fade again.

Palantir is reportedly building a “spy machine” for the Trump administration. William Blair remains bearish on PLTR shares for the remainder of 2025.

Bankers don’t expect “Trump Bump” will boost mergers this year

Leading broker William Blair, an erstwhile cynic has recently upgraded the stock.

Axsome's AXS-12 met Phase 3 trial goals, cutting cataplexy attacks by 77% over six months and improving cognition with a favorable safety profile.